For decades, the public has been told a simple story about radiofrequency (RF) radiation:

• If it doesnt heat tissue, it cant matter.

• Nonthermal equals no mechanism.

• And claims about voltagegated ion channelsespecially calcium channelsare unproven and therefore dismissible.

RF Safe is calling time on that narrative.

Because the United States Food and Drug Administration has authorized a cancer therapyTheraBionic P1 (HDE H220001)that works by delivering nonthermal, amplitudemodulated RF electromagnetic fields. The FDAs own overview describes an RF system emitting specific amplitudemodulated (AM) frequencies and states those frequencies may stop cancer cells from dividing. [1]

That alone breaks the nonthermal RF cant do anything claim.

And it gets more specific: the FDA states the device should not be used in people who receive calcium channel blockers. [1]
A calciumchannel contraindication is not something a heatonly model predicts.

So RF Safes argument is straightforward:

If nonthermal, modulated RF can be used as a signal in medicinestrong enough to produce a therapeutic biological effectthen it is scientifically incoherent to insist that nonthermal RF is biologically inert by definition.
The same door can swing both ways. If it can heal, it can harm.

This is not a claim that TheraBionic proves phones cause cancer.
It is a claim that the mechanism categorynonthermal RF interacting with biology through something more than heatinghas now crossed a regulatory threshold into real clinical use.

What the FDA actually authorized (and why that matters)

TheraBionic P1 is authorized under an FDA Humanitarian Device Exemption (HDE) for adults (18) with advanced hepatocellular carcinoma (HCC) who have failed first and secondline therapy. [13]

HDE matters because its not marketing hypeit is a defined FDA pathway. FDA explains that HDE devices are not required to demonstrate reasonable assurance of effectiveness the same way a PMA device is; instead, they must demonstrate probable benefit, and that probable benefit must outweigh risk given the clinical context. [7]

In other words: the FDA is not rubberstamping miracles. It is authorizing access where options are limitedbased on a real evidence package.

The FDAs TheraBionic P1 overview states:

• In a clinical trial of 41 adults, 14 patients (34.1%) had stable disease for more than 6 months. [1]

• The devices AM frequencies may stop cancer cells from dividing and making more cancer cells. [1]

The FDAs Summary of Safety and Probable Benefit (SSPB) provides the engineering and protocol details that mainstream safety discussions typically ignore:

• RF source operating at 27.12 MHz

• Amplitude modulation depth: 85%

• Modulation frequencies ranging from 0.01 Hz to 150 kHz

• A treatment program consisting of repeated cycles of 194 tumorspecific modulation frequencies for 60 minutes

• Treatment is administered three hours per day, split into three separate onehour sessions [3]

This is important because it proves something the thermalonly worldview tries to erase:

Waveform and modulation are treated as medically meaningful design variablesnot irrelevant trivia.

The calciumchannel contradiction nobody wants to address

The strongest academic pushback against VGIC/VGCC mechanisms typically boils down to:
There isnt enough experimental proof that weak RF can affect gating in a biologically relevant way.

But TheraBionic P1 forces a more honest question:

How can the mechanism category be dismissed as implausible when the FDAauthorized device explicitly excludes calcium channel blocker users? [1]

Even if one debates the details of any particular model, the FDAs own contraindication language signals that ionchannel pharmacology matters to the therapys risk/benefit profile. That is not consistent with only heating exists.

What the mechanistic literature shows about TheraBionics selectivity

TheraBionics research chain is unusually transparent for a medical device:

• Early clinical HCC results were published years before authorization. [12]

• Frequencyspecific biological effects in cancer cells (with normalcell sparing) were demonstrated in vitro. [14]

• A mechanistic preclinical paper reports HCC differentiation effects tied to Cav3.2 Ttype calcium channels (CACNA1H) and Ca influx, providing a plausible selectivity explanation. [11]

RF Safes point is not every step is proven beyond dispute. Its this:

A clinically used, FDAauthorized nonthermal RF therapy has a peerreviewed mechanistic literature that aligns with calciumchannel biology. That makes it intellectually dishonest to claim ionchannel involvement is inherently speculative or impossible.

Where Pall and Panagopoulos fitand what TheraBionic changes

Martin Palls core point

Dr. Martin Palls 2013 review argues that electromagnetic fields can act through voltagegated calcium channels and that downstream effects can be either beneficial or adverse depending on context. [8]

Whether one agrees with every inference in that literature, Palls thesis is explicitly compatible with a simple biological reality:

• Ionchannel gating is electrically sensitive biology.

• Perturb it the right way and you can trigger cascadescalcium signaling, oxidative stress responses, gene expression shifts.

TheraBionics FDA authorization strengthens the plausibility of that category of mechanismnot because it proves every claim, but because it proves the door exists.

Dimitris Panagopoulos emphasis on modulation and nonthermal pathways

Panagopoulos work emphasizes that RF in real life is often not a pure, featureless carrierit includes modulation, pulsing, and variability that can introduce biologically relevant components. His reviews focus on voltagegated ion channel dysfunction and downstream oxidative stress/DNA damage pathways. [910]

TheraBionic P1 is literally designed around that idea: a carrier frequency with a structured modulation program over a wide band (down into extremely low frequencies). [3]

So when people say theres no mechanism, RF Safes response is:

A mechanism category that can be engineered into an FDAauthorized oncology device is not a fantasy. Its a design principle.

What this doesand does notprove

RF Safe is not claiming that TheraBionic P1 alone proves:

• cell phones cause brain cancer, or

• every environmental RF exposure produces clinically meaningful harm, or

• every mechanism proposed in the nonthermal literature is correct.

But TheraBionic P1 does prove something that matters more than most people realize:

1. Nonthermal RF can be biologically active when delivered with specific modulation. [1,3]

2. Calciumchannel biology is relevant enough to appearin FDA contraindications for this therapy. [1]

3. The only heating matters story is therefore not a complete account of biological reality.

Once thats acknowledged, the debate changes.

The argument can no longer be nonthermal effects are impossible.
It becomes: Under what exposure conditions, waveforms, durations, and biological contexts do nonthermal effects appearand how should safety standards reflect that?

That is the conversation RF Safe is demanding.

The policy implication: stop pretending waveform doesnt matter

If medicine can use nonthermal, modulated RF as a targeted biological input, then safety frameworks that treat RF as a heatonly hazard are missing a category of interaction that is now clinically demonstrated.

RF Safes position is that regulators and academic reviewers should stop using lack of consensus as a substitute for:

• direct mechanistic experiments (e.g., patch clamp under controlled modulation vs CW vs sham), and

• biologically grounded limits that account for time, modulation, pulsing, and cumulative exposure rather than just averaged heating proxies.

Because the real-world precedent now exists:

Nonthermal RF is being used to influence biology on purpose. [1,3]

And the public deserves to know that.

References (full URLs)

[1] FDA overview: TheraBionic P1 – H220001

https://www.fda.gov/medical-devices/recently-approved-devices/therabionic-p1-h220001

[2] FDA HDE database entry (TheraBionic P1; HDE original)

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=512962

[3] FDA Summary of Safety and Probable Benefit (SSPB) PDF (H220001B)

https://www.accessdata.fda.gov/cdrh_docs/pdf22/H220001B.pdf

[4] FDA Approval Order PDF (H220001A)

https://www.accessdata.fda.gov/cdrh_docs/pdf22/H220001A.pdf

[5] FDA Labeling PDF (H220001C)

https://www.accessdata.fda.gov/cdrh_docs/pdf22/H220001C.pdf

[6] FDA Labeling Part 2 PDF (H220001D)

https://www.accessdata.fda.gov/cdrh_docs/pdf22/H220001D.pdf

[7] FDA: Getting a Humanitarian Use Device to Market (HDE “probable benefit” standard)

https://www.fda.gov/medical-devices/humanitarian-device-exemption/getting-humanitarian-use-device-market

[8] Pall ML (2013) “Electromagnetic fields act via activation of voltage-gated calcium channels…”

https://pmc.ncbi.nlm.nih.gov/articles/PMC3780531/

[9] Panagopoulos DJ et al. (2021) review (Ion forced-oscillation / VGIC dysfunction / oxidative stress / DNA damage)

https://pmc.ncbi.nlm.nih.gov/articles/PMC8562392/

[10] Panagopoulos DJ (2025) review (comprehensive mechanism)

https://pmc.ncbi.nlm.nih.gov/articles/PMC12179773/

[11] Jimenez H et al. (2019) EBioMedicine (HCC differentiation; Cav3.2/CACNA1H; Ca2+ influx)

https://pmc.ncbi.nlm.nih.gov/articles/PMC6604666/

[12] Costa FP et al. (2011) Br J Cancer (advanced HCC clinical study; free full text)

https://pmc.ncbi.nlm.nih.gov/articles/PMC3188936/

[13] Barbault A et al. (2009) J Exp Clin Cancer Res (tumor-specific frequencies; free full text)

https://pmc.ncbi.nlm.nih.gov/articles/PMC2672058/

[14] Zimmerman JW et al. (2012) Br J Cancer (proliferation inhibited by specific modulation frequencies; free full text)

https://pmc.ncbi.nlm.nih.gov/articles/PMC3261663/

[15] Blackstock AW et al. (2021) 4open (pooled analysis; PubMed/PMC + publisher PDF)

https://pubmed.ncbi.nlm.nih.gov/41550248/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12805502/

https://www.4open-sciences.org/articles/fopen/pdf/2021/01/fopen210003.pdf